-
Bitter pill or market opportunity – how will EU pharma adapt to RFK Jr’s health reforms?
Fredrik Erixon comments in Euractiv on EU sector for R&D-based...
-
How could Britain and the EU work together to improve health?
The study "Negotiating Uncertainty in UK-EU Relations: Past, Present, and Future" by David Henig is mentioned in a piece of the Nuffield...
-
“What would be left of me?” Patient perspectives on the risks of obesity treatment: An innovative health initiative stratification of obesity phenotypes to optimise future obesity therapy (IMI2 SOPHIA) qualitative study
The study "Investing in Obesity Treatment to Deliver Significant Healthcare Savings: Estimating the Healthcare Costs of Obesity and the Benefits of...
-
Reverse Shoulder Arthroplasty versus Non-Operative Treatment of Three-Part and Four-Part Proximal Humerus Fractures in the Elderly Patient: A Pooled Analysis and Systematic Review
The study "What Is Driving the Rise in Health Care Expenditures? An Inquiry into the Nature and Causes of the Cost Disease" by Fredrik Erixon and...
-
Life science i fokus på EU-seminarium
Fredrik Erixon participates in an event organised by Lif on EU lagging behind the US in life sciences and Sweden's opportunities to grow in the...
-
EU’s new China posture takes shape with fresh tool
Oscar Guinea comments in Politico Morning Trade newsletter on EU IPI investigation over Chinese procurement of medical...
-
China keen to boost medical devices production
The ECIPE paper "Strategic Autonomy and the Competitiveness of Europe’s Innovative Pharmaceutical Sector: A Wake-up Call" is referenced in an...
-
Strategic Autonomy and the Competitiveness of Europe’s Innovative Pharmaceutical Sector: A Wake-up Call
Oscar Guinea presents at the European Confederation of Pharmaceutical Entrepreneurs...
-
Covid-19: what the EU can learn from the United States
Matthias Bauer attending an EP hearing on Strategic Autonomy and the resilience of pharmaceutical value chains in the...
-
Covid-19: what the EU can learn from the United States
Matthias Bauer attending an EP hearing on Strategic Autonomy and the resilience of pharmaceutical value chains in the...